Implanet Presents the Clinical Results of its JAZZ Implant in Adolescent Scoliosis Surgery

BORDEAUX, France & BOSTON--()--Regulatory News:

IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible) (Paris:IMPL), a medical technology company specializing in vertebral and knee-surgery implants, today announces the publication of the “Adolescent Idiopathic Scoliosis Treated by Posteromedial Translation Using Jazz Sublaminar Bands” White Paper available on www.implanet.com.

This study, carried out by the Department of Pediatric Orthopedic Surgery at the Robert Debré hospital, which is part of Paris Diderot University, includes details of the results obtained with the help of the JAZZ implant in the surgical treatment of adolescent idiopathic scoliosis by posteromedial translation, in particular in terms of the restoration of frontal and sagittal alignment. The study was conducted with 12-month follow-up of a consecutive series of 20 patients.

Alain Meunier, Implanet’s Clinical & Scientific Affairs Director, comments: “These interim results of a major multi-centre study carried out with the JAZZ system confirm two pivotal parameters: clinical efficiency and patient safety. For Implanet, these results validate, from a clinical perspective, the concept of sublaminar bands in the treatment of adolescent scoliosis.

This post-market study supplements the clinical data that has enabled the JAZZ implant to receive the CE mark in 2011 and FDA (Food & Drug Administration) clearance in 2012. For our team and partners, these results represent the validation of our development and innovation strategy. We are continuing our research to permanently improve the surgical procedure and the care provided to patients suffering from serious spinal deformity, with particular focus on adolescent conditions”, concludes Ludovic Lastennet, CEO of Implanet.

Next financial press release: results for the first half of 2014, on 15 September, 2014

About IMPLANET
Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 38 staff and recorded 2013 sales of €6.7 million.
For further information, please visit www.implanet.com

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (0)5 57 99 55 55
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr
or
NewCap
Press Relations
Nicolas Merigeau, Tel.: +33 (0)1 44 71 94 98
implanet@newcap.fr

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (0)5 57 99 55 55
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr
or
NewCap
Press Relations
Nicolas Merigeau, Tel.: +33 (0)1 44 71 94 98
implanet@newcap.fr